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Introduction
Rituximab is an anti-CD20 monoclonal antibody that
has proven to be effective in the treatment of ANCA-
associated vasculitis (AAV) in adults. Standard treat-
ments rely on corticosteroids and cyclophosphamide.
Only isolated case reports of pediatric AAV treated by
rituximab have been reported so far.
Objectives
Our objective was to collect clinical data and outcomes
of children with AAV treated with rituximab in a multi-
center retrospective study.
Methods
We conducted a retrospective study within the French
paediatric rheumatology society (SOFREMIP) in 2011-
2012.
Results
We identified 6 children with AAV treated with rituxi-
mab (microscopic polyangeitis, n = 2, granulomatosis
with polyangeitis, n = 2, unspecified vasculitis, n = 2).
The age at onset ranged from 4 to 16 yrs. Treatment
with rituximab consisted in 4 infusions of 375 mg/m2;
one patient received only 3 infusions. Mean duration of
follow-up was 2.65 yrs. All patients achieved clinical
remission after 12 months. One patient presented sev-
eral relapses associated with B cell increase and was
dependent on rituximab infusions. No severe adverse
event had been reported.
Conclusion
From this multicenter retrospective series, short-term
safety and efficicacy of rituximab in pediatric AAV is
promising so that B cell depleting agents may represent
an alternative to conventional treatment with cyclopho-
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